ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Nie, W; Wang, ZJ; Zhang, K; Li, B; Cai, YR; Wen, FC; Zhang, D; Bai, YZ; Zhang, XY; Wang, SY; Cheng, L; Zhong, H; Liu, L; Wang, J; Han, BH

Zhong, H; Han, BH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China.;Wang, J (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.;Liu, L (通讯作者)，Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.

BMC MEDICINE, 2022; 20 (1):

Abstract

Background In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) w......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索